Novo Nordisk, a leading global healthcare company, announced that the US Food and Drug Administration (FDA) accepted its New Drug Application (NDA) submission for an investigational once-daily, 25 mg ...

Findings showed a 13.6% reduction in body weight in the semaglutide 25 mg group compared with a 2.2% reduction in the placebo group. The Food and Drug Administration (FDA) has accepted for review ...

PLAINSBORO, NJ, USA I May 2, 2025 I Today, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) submission for an investigational once-daily, ...

25 mg oral formulation of Wegovy® (semaglutide) for chronic weight management in adults living with obesity or overweight with one or more comorbid conditions and to reduce the risk of major ...

Ascendis Pharma A/S announced that its Board of Directors approved a plan to allocate approximately $25 million in the first quarter of 2025 for a share repurchase program and the net settlement ...

Ascendis Pharma launches $25 million share buyback Open in App Get 45% Off Sign In Free Sign Up ...

Ascendis Pharma launches $25 million share buyback View all comments (0) 0 Latest comments Post Comment Guidelines Trade With A Regulated Broker Indices Commodities Bonds Stocks US 30 42,166.00 ...

After going hands-on with lots and lots of new tech, here’s the top 25 gadgets of CES. And be sure to check out our list of the weirdest CES 2025 gadgets, too. The Samsung Frame was already a ...

Ascendis Pharma (ASND) said the FDA has accepted for its supplemental Biologics License Application for TransCon hGH for the treatment of adult growth hormone deficiency, or GHD. The agency has ...

Ascendis Pharma's supplemental application for ... or daily hGH based on age and oral estrogen intake with approximately equivalent hGH mg/week for TransCon hGH and daily hGH.